CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 731 enrolled
Drug / intervention
Radical prostatectomyprocedure
Likely dose
Radical prostatectomy (surgical intervention - no pharmacologic dose)AI-extracted
Key inclusion· 3
  • Clinically localized prostate cancer
  • Diagnosis within previous 6 months
  • Age 75 years or younger
Key exclusion· 13
  • PSA greater than 50 ng/ml
  • Evidence of metastatic disease on bone scan
  • Cancer not clinically localized
  • Diagnosis more than 12 months ago

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00007644
NCT00007644Phase 3Completed

CSP #407 - Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer

VA Office of Research and Development·interventional·Posted Jan 1, 2001·Updated Feb 24, 2020

In Brief

A Phase 3 clinical trial evaluating Radical prostatectomy for Prostate Cancer. Completed, enrolled 731 participants across 31 sites.

Detailed Summary

Radical prostatectomy provides potentially curative removal of the cancer. However, it subjects patients to the morbidity and mortality of the surgery and may be neither necessary nor effective. Expectant management does not offer potential cure. However, it provides palliative therapy for symptomatic or metastatic disease progression, avoids potentially excessive and morbid interventions in asymptomatic patients, and emphasizes management approaches for focus on relieving symptoms while minimizing therapeutic complications. The primary objective of this study is to determine which of two strategies is superior for the management of clinically localized CAP: 1) radical prostatectomy with early aggressive intervention for disease persistence or recurrence, 2) expectant management with reservation of therapy for palliative treatment of symptomatic or metastatic disease progression. Outcomes include total mortality, CAP mortality, disease free and progression free survival, morbidity, quality of life, and cost effectiveness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States

Timeline

Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 1, 2001
Enrollment StartNov 1, 1994
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 15.2 yearsPosted 25.5 years ago

Interventions

Radical prostatectomyprocedure

Surgical removal of the prostate